EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Related Keywords

Australia ,Japan ,Tokyo ,New Zealand ,Massachusetts ,United States ,China ,Cambridge ,Cambridgeshire ,United Kingdom ,Russia ,Haruo Naito ,Charles Weissmann ,Walter Gilbert ,Heinz Schaller ,Christophera Viehbacher ,Mike Hencke ,Natacha Gassenbach ,Kenneth Murray ,Prnewswire Eisai Co Ltd ,Communications Department ,Linkedin ,Twitter ,Investor Relations Department ,National Institute On ,Eisai Europe Ltd ,Biogen Inc ,Nasdaq ,Facebook ,Public Relations Department ,National Institutes Of Health ,Drug Administration ,Eisai Inc ,Washington University School Of Medicine ,Exchange Commission ,Eisai Co Ltd ,Youtube ,Alzheimer Network Trials Unit ,European Medicines Agency ,National Medical Products Administration ,United Nations Sustainable Development Goals Sdgs ,Alzheimer Clinical Trial Consortium ,Brand Name ,Clinical Dementia Rating Sum ,New England Journal ,Supplemental Biologics License Application ,Dose Management ,Carrier Status ,Antithrombotic Medication ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Confidence Interval ,Corporate Concept ,United Nations Sustainable Development Goals ,Sir Kenneth Murray ,Nobel Prize ,Private Securities Litigation Reform Act ,